Abstract The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS) accumulation play critical roles in DOX-induced cell death. However, the novel targets and pharmacological agents combating DOX resistance in OS via mitochondrial homeostasis and DOX-induced cell death manipulation is poorly understood.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Fengkun
Contact Fengkun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack